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1117-85 Influence of Body Mass Index on Acute Coronary 
Syndrome Outcomes: Lessons From the Global 
Registry of Acute Coronary Events
Kamala Tamirisa, Dietrich C. Gulba, Catherine Kim, Martin Klutmann, Christoph 
Tillmans, Kami White, Kim A. Eagle, The GRACE Investigators, University of Michigan 
Medical School, Ann Arbor, MI, Krankenhaus Düren, Düren, Germany
Background The relationship between body mass index (BMI) and acute coronary syn-
drome (ACS) outcomes is controversial. The aim of this study was to investigate the risk
profile and outcomes of ACS patients according to BMI category.
Methods We examined data from 19,318 patients enrolled in the GRACE registry.
Patients were stratified into BMI categories (kg/m2): <20, 20-25, >25-30, >30. Assessed
outcomes included hospital mortality, bleeding and stroke rates. Logistic regression was
used to adjust analyses for baseline characteristics and ACS type.
Results Of the 19,318 ACS patients, when compared to reference patients (BMI 20-25),
those with BMI >30 had more diabetes mellitus, hypertension, hyperlipidemia and diag-
nostic coronary angiograms, whereas BMI <20 had more heart failure and smoking his-
tory. Older patients had lower BMI compared to younger patients. On further
stratification, death rates were higher in >70 years of age in all BMI groups and either
gender, except in males with BMI <20, where the mortality was similar in both age
groups. We found no association between BMI and hospital mortality in men with ACS.
Women with BMI <20 had a trend toward higher hospital mortality compared to reference
(Table 1) and received less CABG.
Conclusions Women (particularly those >70 years) with ACS and BMI <20 showed a
trend for increased hospital mortality after adjustment for clinical characteristics. There
was no association between BMI and ACS outcomes in men.
1117-86 Do Differing C-Reactive Protein Assay Methods Impact 
Cardiovascular Risk Assessment?
Jessica L. Clarke, Jeffrey L. Anderson, John F. Carlquist, Richard F. Roberts, Benjamin 
D. Horne, Tami L. Bair, Matthew J. Kolek, Chrissa P. Mower, Ashle M. Crane, Ted J. 
Hollist, William L. Roberts, Joseph B. Muhlestein, LDS Hospital, Salt Lake City, UT, 
University of Utah, Salt Lake City, UT
Background: Serum C-reactive protein (CRP) is acknowledged as an independent risk
marker for primary and secondary prevention of coronary artery disease (CAD). Several
assays are available and have been used; however, little information is available about
their comparability, especially in diseased populations.
Methods: Two assays were compared in a cohort of 805 consenting patients who had
blood drawn during angiography for suspected or known CAD and were followed for 2.6 ±
1.3 y. Frozen samples from the patients were tested by a particle-enhanced immunoturbi-
dimetric assay (Tina-quant, Roche, R) and by a fluorescence polarization immunoassay
(Abbott, A). CRP analysis was performed non-parametrically or after logarithmic (ln)
transformation or division into quartiles (Q). Spearman’s test was used for correlations
and logistic regression for predictive modeling.
Results: The study population had an average age of 62 years; 73% were male; 26%,
smokers; 78% had angiographic CAD; 62%, hypertension; 69%, hyperlipidemia; 25%,
diabetes; and 16%, prior MI. During follow-up, 168 events occurred. Median CRP differed
substantially by assay overall (A=13.4, R=3.21 mg/L) and in those without (N=176) and
with (N=627) CAD. However, correlations of lnCRP-A vs. lnCRP-R were high (r=0.824,
p<<0.001); 4Q CRP assays were congruent in 88% of pt and within 1 Q in 98% by both
assays. Overall, 65% of tests were congruent and 96% within 1 Q. Both assays indepen-
dently predicted death/nonfatal MI (D/MI), with 4Q vs. 1Q odds ratio (OR) for CRP-
A=1.78 (1.11-2.84) and for hsCRP-R=1.90 (1.17-3.10) in stepwise modeling including 7
standard risk factors. CRQ-A also independently predicted angiographic CAD (p=0.007),
4Q/1Q OR=1.67.
Conclusion: Although the absolute CRP values differed substantially between the two
assays in our large study were substantial (4-fold difference in median values), they were
highly correlation by Q rank and equally predictive of D/MI. These results emphasize the
robust within-assay predictive value of CRP and should assist in comparing values deter-
mined from various assays across different studies and in standardizing assay methods
for the future.
1117-87 Does the Presence of Q Waves in the Infarct-Leads at 
the Presentation of an ST Elevation Myocardial 
Infarction Predict 30-Day Outcome After Fibrinolytic 
Therapy? Results From the HERO-2 Trial
Cheuk-Kit Wong, Harvey D. White, The HERO-2 Investigators, Green Lane Hospital, 
Auckland, New Zealand, Dunedin Medical School, Dunedin, New Zealand
Background: The evolution of pathological Q waves in the infarct leads during a ST ele-
vation acute myocardial infarction reflects ongoing myocardial necrosis.
Aim: We determined if the presence of pathological Q waves in the infarct leads at pre-
sentation would predict 30-day mortality after fibrinolytic therapy.
Methods and results: In 15,222 patients with ST elevation during normal intraventricular
conduction randomised in the Hirulog Early Reperfusion Occlusion (HERO) –2 trial,
10,244 patients (67.3%) had and 4,978 (32.7%) did not have initial Q waves. All patients
received aspirin, streptokinase and either unfractionated heparin or bivalirudin. The 30-
day mortality was higher in patients with than in patients without initial Q waves (10.2%
vs 6.9%, P<0.0001). In the 12,456 patients who also satisfied the criteria for analysing
ST resolution at 60-minute, patients with initial Q waves had less frequent ST resolution
than patients without initial Q waves (51.7% vs 56.9% for >30% ST resolution, P<0.0001;
and 12.9% vs 18.9% for >70% ST resolution, P<0.0001). These differences in mortality
and ST resolution were seen in all subgroups stratified by time to randomization or by inf-
arct-location, and in patients who had a first infarction.
On multivariable analysis including usual clinical prognostic predictors, the presence of
initial Q waves independently predicted 30-day mortality (P<0.0001). In a second model
including also ST measurements in the 12,456 patients, Q waves in the infarct leads
remained significant in predicting higher 30-day mortality (adjusted odds ratio 1.31, 95%
confidence interval 1.12-1.54; P<0.0001). There was an early separation of the survival
curves of patients with and patients without initial Q waves. Other electrocardiographic
predictors were baseline ST elevation, baseline ST depression and resolution of ST ele-
vation at 60 minutes. There was no interaction between initial Q waves and 60-minute ST
resolution in predicting 30-day mortality (P=0.619).
Conclusion: Q wave in the infarct lead group at the presentation of a ST elevation acute
myocardial infarction independently predicted a higher 30-day mortality.
1117-88 High-Density Lipoprotein, but Not Low-Density 
Lipoprotein Cholesterol Levels Influence Short-Term 
Prognosis After Acute Coronary Syndrome: Results 
From the MIRACL Trial
Anders G. Olsson, Gregory G. Schwartz, Michael D. Ezekowitz, Peter Ganz, Michael F. 
Oliver, David Waters, Andreas Zeiher, William Sasiela, Michael Szarek, The MIRACL 
Trial Investigators, University of Linkoping, Linkoping, Sweden, VA Medical Center and 
University of Colorado Health Sciences Center, Denver, CO
The MIRACL trial demonstrated that intensive treatment with atorvastatin, initiated
shortly after acute coronary syndrome (ACS), reduces early recurrent ischemic events.
The present prespecified analysis determined the influence of serum lipoprotein concen-
trations and treatment on short-term outcomes after ACS. Methods: Cox proportional
hazards models determined relations among lipoproteins, treatment (atorvastatin 80 mg
daily or placebo), and time to a primary endpoint event (death, nonfatal AMI, cardiac
arrest, or urgent rehospitalization for recurrent myocardial ischemia) during the 16-week
trial. One analysis related lipoproteins measured at baseline (prior to treatment) to events
from randomization to Week 16. Another analysis related the change in lipoproteins from
baseline to Week 6 (on treatment) to events occurring during Weeks 6-16. Hazard ratio
(95% CI) for a recurrent ischemic event was expressed per mg/dl increase in a lipopro-
tein measurement. Results: There was no independent influence of baseline total cho-
lesterol, triglycerides, or LDL-C on 16 week risk of an ischemic event, with a hazard ratio
of 1.000 (0.997-1.003) for LDL-C. In contrast, higher baseline HDL-C was independently
associated with reduced risk [0.986 (0.979-0.994, p<.001]. Stated another way, each mg/
dl increment in baseline HDL-C reduced risk of an event by 1.4%. In multivariate analy-
sis, assignment to treatment with atorvastatin, compared to placebo, was associated with
reduced risk of an ischemic event, with hazard ratio 0.835 (0.699-0.999). Although atorv-
astatin reduced LDL-C by 55% compared to placebo at 6 weeks, the change in LDL-C on
randomized treatment had no effect on the risk of an event [1.001 (0.995-1.004)]. Atorv-
astatin had no significant effect on HDL-C at 6 weeks. Conclusions: Short-term progno-
sis after ACS is not influenced by baseline levels of LDL-C, but is favorably influenced by
higher baseline levels of HDL-C. The reduction in early recurrent ischemic events after
ACS with atorvastatin cannot be explained by the concurrent reduction in LDL-C, sug-
gesting that mechanisms unrelated to circulating lipoproteins (pleiotropic effects) may be
responsible for the clinical benefit.
1117-89 The Acuteness Score: New Insights in Predicting Infarct 
Size
Jacobus S. de Villiers, Yuling Fu, Galen Wagner, Shaun G. Goodman, Christopher B. 
Granger, Lars Wallentin, Frans Van de Werf, Paul W. Armstrong, for the ASSENT 3 
Investigators, University of Alberta, Edmonton, AB, Canada
Background: Early fibrinolytic therapy reduces mortality in acute ST elevation myocar-
dial infarction (MI). Since symptom onset time is subjective we adapted a previously
developed Acuteness Score (AS) that uses phasing of ST, T and Q waves to provide a
potentially more objective measurement of the evolutionary status of an MI (earliest 4.0
to latest 1.0). We used the ASSENT-3 ECG data to validate the usefulness of the AS by
evaluating its relationship to ST resolution (STR) 60 minutes after fibrinolysis and to inf-
arct size as assessed by discharge QRS score.
Methods: A total of 4272 pts from the ASSENT 3 study were stratified into 2 groups
based upon a previously established cut point of high (AS >3), 2727(63.8%) or low acute-
ness (AS <3), 1545(36.2%).
Table 1: BMI and In-hospital Death in Women
BMI (kg/m2) Crude Mortality Adjusted Mortality Adjusted OR (CI)
<20 10.8% 7.4% 1.5 (0.96, 2.28)
20-25 6.7% 5.3% Reference
>25 5.0% 5.1% 0.96 (0.73, 1.26)
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Results: At 60 min, 850/2192 pts with AS >3 had an 11% greater absolute frequency of
complete STR (>70%) than 344/1239 with low AS (<3) p <0.001. Patients surviving to
discharge (fig.), showed that within each subgroup of STR, patients with high AS were
statistically more likely to have a small QRS infarct at discharge as compared to those
with low AS p<0.001. Moreover in a multivariate logistic regression model including base-
line characteristics, Σ ST, STR, time to treatment, the AS >3proved the strongest predic-
tor of small infarct size (OR=0.374, CI= 0.315-0.445).
Conclusion: Even after adjusting for time to treatment the AS provides novel insight into
the likelihood of STR 60 min after fibrinolysis and the probability of a smaller infarct size
regardless of the extent of STR. 
1117-90 Establishing a New Therapeutic Activated Partial 
Thromboplastin Time Range for Unfractionated Heparin 
for Acute Coronary Syndromes
Michael S. Lee, Venu Menon, Joseph Schappert, James R. Wilentz, Varinder Singh, 
Judith Hochman, St. Luke's-Roosevelt Hospital Center, New York City, NY
Introduction: The therapeutic aPTT range of 50 to 70 sec recommended by the ACC/
AHA for patients receiving unfractionated heparin (UFH) for acute coronary syndromes
(ACS) is vulnerable to variation in test reagents. Rather than use the standard therapeu-
tic aPTT range, it has been recommended that each institution establish its own thera-
peutic aPTT range based upon anti-factor Xa levels. We evaluated our institution's
therapeutic aPTT range by examining the correlation between aPTTs and anti-factor Xa
levels and established a new therapeutic aPTT range with a new thromboplastin reagent
based upon the therapeutic anti-factor Xa levels.
Methods: 62 plasma samples were collected from 26 consecutive patients receiving
UFH for ACS. APTTs measured with a thromboplastin reagent and a new thromboplastin
reagent and anti-factor Xa levels were obtained on each plasma sample. Linear regres-
sion analysis was performed to establish a new therapeutic aPTT range from corre-
sponding therapeutic anti-factor Xa levels.
Results: 32% of patients with target range aPTTs had anti-factor Xa levels below the
accepted level of 0.35-0.7 U/mL for ACS while 68% had therapeutic anti-factor Xa levels.
When the same blood was tested with a new thromboplastin reagent, only 9% of patients
with target range aPTTs had anti-factor Xa levels <0.35 U/mL while 91% had therapeutic
anti-factor Xa levels. The Pearson correlation coefficient (r) for the new thromboplastin
reagent was 0.93. The slope of the regression line was 221.3. The therapeutic aPTT
range established with the new thromboplastin reagent was 61-100 sec.
Conclusion: Monitoring aPTTs without standardizing the thromboplastin reagent may
not adequately reflect therapeutic heparin levels. Despite apparently therapeutic aPTTs,
patients treated with UFH may be under-anticoagulated. Our new anti-Xa-adjusted thera-
peutic aPTT range shows an increase in the positive predictive value of aPTTs. Large-
scale clinical studies are needed to determine the optimal anti-factor Xa range for ACS
patients treated with UFH, with further refinements if GP IIb/IIIa antagonists are concom-
itantly used and to show a clinical benefit for monitoring heparin levels with anti-factor Xa
levels.
1117-91 Invasive Therapy Along With Glycoprotein IIb/IIIa 
Inhibitors and Intracoronary Stents Improves Survival in 
Non-ST-Segment Elevation Acute Coronary Syndromes
Anthony A. Bavry, Dharam J. Kumbhani, Rene Quiroz, Suneil R. Ramchandani, Satish 
Kenchaiah, Harvard School of Public Health, Boston, MA, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Although several clinical trials have shown that early invasive therapy in UA/
NSTEMI patients reduces the risk of composite endpoints inclusive of death, MI or
angina, it is unclear whether such an approach improves survival.
Methods: We conducted a meta-analysis on five studies in a total of 6,766 UA/NSTEMI
patients who were randomized to either routine invasive (n=3,371) versus conservative
therapy (n=3,395) in the era of GP IIb/IIIa inhibitors and intra-coronary stents.
Results: As compared with conservative therapy, an invasive approach was associated
with a reduction in the risk of all-cause mortality at 6-12 months (3.3% vs. 4.2%, relative
risk [RR] 0.80, 95% confidence interval [CI] 0.63 to 1.03) and at 24 months (5.0% vs.
6.5%, RR 0.77, 95% CI 0.60 to 0.99) of follow-up. Although invasive therapy reduced the
risk of the composite endpoint of death or MI at 6-12 months in men (RR 0.68, 95% CI
0.57 to 0.81) and troponin positive patients (RR 0.74, 95% CI 0.59 to 0.94), the results for
women (RR=1.07, 0.82 to 1.41) and troponin negative patients (RR=0.82, 0.59 to 1.14)
were equivocal. 
Conclusions: Invasive therapy in UA/NSTEMI patients with adjunctive use of GP IIb/IIIa
inhibitors and intra-coronary stents improves survival. Enhanced risk stratification is
needed in women and troponin negative patients so that invasive therapy may be more
effectively recommended in these groups. 
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1118-77 Effects of Carvedilol Compared to Atenolol on Ejection 
Fraction and Clinical Endpoints After Myocardial 
Infarction
Gisli Jonsson, Michael Abdelnoor, Carl Müller, Sverre Erik Kjeldsen, Ingrid Os, Arne 
Westheim, Ullevaal University Hospital, Oslo, Norway
Background: Beta-blockers have been found to reduce mortality and morbidity in post-
myocardial infarction (MI) patients. However, it is not fully understood, whether all beta-
blockers have similiar favourable cardiovascular effects. The aim of this study was to
compare the effects of carvedilol and atenolol on global and regional ejection fraction
(EF), and on predefined cardiovascular endpoints.
Methods: In a randomized, prospective, open and endpoint-blinded single center study,
118 patients received carvedilol (mean dosage 36.2 + 15.1 mg) and 114 patients atenolol
(mean dosage 72.1 + 30.6 mg). No difference in baseline data, such as age, gender,
race, smoking, hypertension, dibetes mellitus or lipid lowering treatment, was observed.
There was no difference in baseline characteristics regarding infarct localization, reperfu-
sion therapy and acute treatment between the groups. Treatment with aspirin (96%), sta-
tin (98%), and ACE-inhibitors was equal in the 2 groups. The global and regional left
ventricular (LV) EF were evaluated with gated blood pool scintigraphy.
Results: In the carvedilol group 90 cardiovascular endpoints were observed compared
to 104 endpoints in the atenolol group, with a hazard ratio (RR) 0.84 with 95% confidence
interval (0.74-0.94) (p=0.002). This occured despite similar global LVEF was 55 + 11% at
baseline, 57 + 10% at 3 months and 57 + 10% at 12 months in the carvedilol group and
53 + 9%, 56 + 10% and 56 + 9% in the atenolol group respectively. No difference in
regional EF was observed in the two groups. The main contributor to the difference in
cardiovascular endpoints was a composite of cardiovascular deaths, non-fatal MI, and
congestive heart failure (worsening and hospitalization).
Conclusion: In patients following an acute MI, carvedilol treatment compared to atenolol
was associated with a significant reduction in combined cardiovascular endpoints despite
that no difference in global or regional ejection fractions was found. Thus other mecha-
nisms than remodelling might explain this difference in clinical effect between the two
drugs.
1118-78 Primary Angioplasty Versus Facilitated Intervention 
(Tenecteplase Plus Stenting) in Patients With ST 
Elevated Acute Myocardial Infarction: Final Results of 
the GRACIA-2 Trial
Francisco Fernandez-Aviles, Joaquin J Alonso, Alfonso Castro-Beiras, Javier Goicolea, 
Jesus Blanco, Juan Alonso, Juan Lopez-Mesa, Luis Diaz-Llera, Nicolas Vazquez, Rosa 
Hernandez, Armando Perez, Javier Moreu, The GRACIA-2 Investigators, ICICOR, 
Hospital Clinico Valladolid, Valladolid, Spain
Background: Combined reperfusion therapies widely applicable could benefit the still
high proportion of patients (pts) with ST-elevated acute myocardial infarction (STEAMI)
for whom primary PCI is not available due to logistic reasons.
Methods: We compared the evolution of 212 pts with STEAMI (<12 hs from onset) ran-
domised to 2 strategies: 1) primary PCI optimally performed (stenting of culprit artery
under protection of abcximab within 3 hs from onset); or 2) a combined (facilitated) strat-
egy: immediate thrombolysis (T) with tenecteplase (full bolus dose adjusted by weight)
